Barclays initiates Merus stock with Overweight rating, $112 price target

Barclays initiated coverage on biopharmaceutical company Merus N.V. (MRUS) with an Overweight rating and a $112 price target, citing its validated antibody platform, strong revenue growth, and the significant potential of its Phase 3 asset, petosemtamab, for head and neck cancers, with initial data expected in 2026. This positive outlook is echoed by BofA Securities, which reiterated its Buy rating and $92 target, naming Merus a top pick for 2025 due to petosemtamab's promising efficacy and advancement towards registrational development. The company's shares have already surged 59.1% year-to-date, reflecting robust market confidence in its clinical pipeline.

Analysis

Merus N.V. (MRUS) has received strong endorsements from Wall Street, with Barclays initiating coverage at an Overweight rating and a $112 price target, and BofA Securities reiterating a Buy rating with a $92 target, designating it a top pick for 2025. This bullish sentiment is built upon the company's validated antibody platform and strong financial performance, evidenced by nearly 60% revenue growth in the last twelve months. The primary catalyst for future valuation is petosemtamab, a Phase 3 clinical asset for head and neck cancers, which BofA notes has exceeded expectations on efficacy and safety. The market has already responded favorably, with the stock surging 59.1% year-to-date to trade near its 52-week high. However, the key inflection point for petosemtamab, the initial topline data from its Phase 3 trials, is not anticipated until 2026. Barclays suggests a degree of downside protection exists due to the commercial validation of Merus's platform through its approved drug, zenocutuzumab, which partially derisks the technology.

Key Decisions for Investors

• Given the strong analyst consensus and promising pipeline, investors with a long-term horizon could consider the stock, but must be mindful that the significant 59.1% year-to-date gain has priced in considerable optimism.
• The primary investment thesis hinges on a long-duration catalyst, as key Phase 3 data for petosemtamab is not expected until 2026, introducing timeline risk and requiring patience.
• Investors should monitor any interim clinical updates on petosemtamab's registrational development and the company's ability to sustain its nearly 60% LTM revenue growth as key performance indicators.
• The discrepancy between Barclays' $112 and BofA's $92 price targets, despite both being bullish, suggests investors should conduct their own valuation to assess the potential upside from current levels.